A method of determining a duration of safe apnoea. Information is obtained relating to a respiratory indicator, and a duration of safe apnoea is determined from the obtained information. A respiratory therapy system has one or more patient interfaces. A processor is configured to determine a duration of safe apnoea based on obtained information relating to a respiratory indicator.

Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed.

Embodiments of the present disclosure provide systems and devices for delivering gaseous Nitric Oxide (gNO) under therapeutic parameters to reduce infection in a subject. Certain embodiments include devices and systems for delivering pressurized gNO to reduce bioburden and promote healing in the wounds of subjects having various disease conditions, including skin and soft tissue infections (SSTIs) and osteomyelitis. In some embodiments, the present disclosure provides portable wound healing devices for delivering pressurized gNO to the site of a wound to treat various disease conditions in a subject. Other embodiments relate to systems and devices for delivering and for monitoring gaseous Nitric Oxide (gNO) under therapeutic parameters of use to treat a subject. In certain embodiment, the devices include a subject interface unit comprising sensors for detecting gNO pressure and/or gNO flow.

The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO.sub.2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO.sub.2-to-NO reactor cartridge and/or a breakthrough of NO.sub.2, and providing an indication of the remaining useful life and/or breakthrough.

The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO.sub.2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO.sub.2-to-NO reactor cartridge and/or a breakthrough of NO.sub.2, and providing an indication of the remaining useful life and/or breakthrough.

A device for generating nitric oxide is disclosed. The device is configured for applying to either a body cavity or a surface of a subject in need thereof. Also disclosed is a method for the treatment of diseases or conditions with the device.

Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.

Described are methods for improving oxygen saturation in patients suffering from hypoxemia, wherein said patients are receiving a continuous flow of oxygen at 10 L/min and exhibit an initial oxygen saturation of at least about 88%, comprising administering inhaled nitric oxide to said patients in an outpatient setting. Methods for improving quality of life for a hospitalized patient, reducing patient hospitalization time, and reducing costs associated with patient hospitalization are also described.

Disclosed embodiments relate to a wound dressing which can generate nitric oxide. The wound dressing may include a cover layer, an activator layer such as an acid providing layer and nitric oxide source layer, such as a nitrite providing layer. The activator layer may include acidic groups and may be hydrogel, xerogel, or other suitable material. The nitric oxide source layer may include a nitrite salt. Nitrite ions of the nitric oxide source layer may react with the acidic groups of the activating layer to generate nitric oxide. The activating layer may include a window at the center, and a central absorbent material may be positioned at the window. Various separating layers may also be incorporated into the dressing to control the interaction between activating layer and nitric oxide source layer.

The present disclosure relates to use of pulsed dose inhaled nitric oxide for treatment of infection, including infection with SARS-CoV2 and the disease state COVID-19.